Abstract 14139: New Criteria of Electrocardiographic Diagnosis of Left Ventricular Hypertrophy Were Associated With Cardiovascular Events in Japanese Patients: Japan Morning Surge Home Blood Pressure (J-HOP) Study
Introduction: The Cornell product (CP) is an electrocardiographic marker of left ventricular hypertrophy(LVH), but has a high false-negative rate. The relationships between the CP and cardiovascular(CV) event may differ between genders or among ethnicities.
Hypothesis: We hypothesized that a new modified CP (MCP) would be associated with a poor prognosis in Japanese patients with CV risk factors.
Methods: Subjects were 3,380 patients enrolled in the Japan Morning Surge Home Blood Pressure Study who had one or more CV risk factors. A CP of ≥2440 mmхms was used to diagnose electrocardiographic LVH (CP-LVH). We also calculated the product of (RaVL+SV3) xQRS (MCP) without adjusting for female gender by adding 8 mm to the sum of (RaVL+SV3). We divided patients into quintiles by the product of MCP, and compared the prognosis of subjects in the highest quintile of MCP (male≥2000 mmхms, female ≥1666 mmхms) with those in the other four quintiles in males and females. The primary endpoints were fatal/nonfatal CV events (myocardial infarction, stroke, hospitalization for heart failure).
Results: During the mean follow-up period of 48±39 months, there were 139 CV events (88 in males, 51 in females). The CV event incidence was not significantly different between subjects with/without CP-LVH either in males (log rank 1.24, p=0.27) or females (log rank 0.16, p=0.69). In male, subjects in the highest quintile (N=315) were more likely to suffer CV events than those in the other four quintiles of MCP (N=1262; log rank 6.10, p=0.014). A Cox proportional hazards model including age, smoking, drinking, hypertension, dyslipidemia and diabetes revealed that the highest quintile of MCP was an independent predictor of CV events in male (hazard ratio 1.76, 95%CI 1.12-2.75). In female, CV events were similar between the highest quintile (N=361) and the other four quintiles of MCP (N=1442).
Conclusions: The highest quintile of MCP was associated with CV events in Japanese male patients with CV risk.
Author Disclosures: Y. Ishiyama: None. T. Kabutoya: None. S. Hoshide: None. K. Kario: Research Grant; Significant; Teijin Pharma Limited, OMRON HEALTHCARE Co., Ltd., FUKUDA DENSHI, Bayer Yakuhin Ltd., A &D Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED., MOCHIDA PHARMACEUTICAL CO., LTD, EA pharma, Otsuka Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan Inc., Mitsubishi Tanabe Pharma Corporation., Medtronic Japan Co., Ltd.. Honoraria; Modest; Mitsubishi Tanabe Pharma Corporation., Kyowa Hakko Kirin Co., Ltd., Bayer Yakuhin Ltd., Pfizer Japan Inc., Shionogi & Co., Ltd., Astellas Pharma Inc, AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Sanofi K.K., TERUMO CORPORATION, Bristol-Myers K.K., Kowa Pharmaceutical Co. Ltd., SANWA KAGAKU KENKYUSHO CO.,LTD., MSD K.K., Actelion Pharmaceuticals Japan, Abott Japan, OMRON HEALTHCARE Co., Ltd., Century Medical Inc., TOA EIYO LTD., MOCHIDA PHARMACEUTICAL CO., LTD, Sumitomo Dainippon Pharma Co., Ltd.. Honoraria; Significant; Takeda Pharmaceutical Company Limited., DAIICHI SANKYO COMPANY, LIMITED., OMRON HEALTHCARE Co., Ltd..
- © 2016 by American Heart Association, Inc.